SCHEMBL67813

SCHEMBL67813

CC(CN1C(=O)c2ccccc2C1=O)NC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
MALT1 Q9UDY8 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
KMT2A Q03164 4/20 0.43
AKT1 P31749 1/20 0.42
CTSS P25774 2/20 0.41
ATM Q13315 1/20 0.41
CTSK P43235 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14923513 1.00 ALDH1A1 (0.43) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL67814 1.00 ALDH1A1 (0.43) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL30664358 0.88 ATM (0.42) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL20757361 0.88 ATM (0.42) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL19300690 0.88 ATM (0.42) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL20974198 0.87 AKT1 (0.43) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL22559290 0.87 AKT1 (0.43) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL5551909 0.87 CA1 (0.50) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL5551910 0.87 CA1 (0.50) ALDH1A1MALT1MMP1MMP2MMP3
SCHEMBL5551903 0.87 CA1 (0.50) ALDH1A1MALT1MMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160024114-A1 MACROCYCLIC RIP2 KINASE INHIBITORS ONCODESIGN S.A. (FR) 2016-01-28 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
WO-2014140299-A1 MACROCYCLIC RIP2 KINASE INHIBITORS ONCODESIGN S.A (FR) 2014-09-18 WO disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-18 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS ALDH1A1 3257/4885MALT1 1770/4885MMP1 4784/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS ALDH1A1 2358/4885MALT1 1001/4885MMP1 4766/4885
US-20160024114-A1 MACROCYCLIC RIP2 KINASE INHIBITORS RIPK2, RIPK1, RIPK3 ALDH1A1 4857/4885MALT1 2099/4885MMP1 4371/4885
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF ALDH1A1 3123/4885MALT1 1008/4885MMP1 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.